EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repair
Open Access
- 13 June 2024
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 226, 116366
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 40 references indexed in Scilit:
- Paris saponins Ⅶ inhibits glycolysis of ovarian cancer via the RORC/ACK1 signaling pathwayBiochemical Pharmacology, 2023
- DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1‐Mediated NRF2 UbiquitinationAdvanced Science, 2023
- Immune checkpoints in osteosarcoma: Recent advances and therapeutic potentialCancer Letters, 2022
- DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implicationsDNA Repair, 2021
- BACH1 Stabilization by Antioxidants Stimulates Lung Cancer MetastasisCell, 2019
- Tumor microenvironment and therapeutic responseCancer Letters, 2017
- EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathwayCancer Letters, 2016
- Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversalTumor Biology, 2015
- EYA4 Acts as a New Tumor Suppressor Gene in Colorectal CancerMolecular Carcinogenesis, 2015
- The Eyes Absent proteins in development and diseaseCellular and Molecular Life Sciences, 2012